VANCOUVER, BC / ACCESS Newswire / November 4, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, ...

MOG-IgG positivity is rare in MS patients, complicating diagnosis and treatment, especially in Asian populations with lower ...

The company now expects full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of ...

Bionxt launched the final animal study needed to prepare for human testing of BNT23001, its under-the-tongue version of ...

Having a higher BMI at diagnosis is tied to faster disability progression in people with multiple sclerosis, according to a ...

BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...

New deal builds on the success of a longstanding partnership in retinal health and the potential of CDR-Life’s unique antibody fragment-based ...

The breakdown of myelin, the insulating layer around brain cells that supports brain function, is prevalent in a range of ...

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

Presented recent updates on fibroblast-based therapies for chronic disease treatments at the Cell & Gene Meeting on the Mesa, H.C. Wainwright 27th Annual Global Investment Conference, and the 2025 ...

Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients Prepa ...

TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.